• About Amgen
  • Science
  • Corporate Giving
  • Site Map
  • Search
  • Privacy & Terms
  • Contact Us
Amgen
  • Patients
  • Medical Professionals
  • Partners
  • Investors
  • Careers
  • Media
  • print
  • mail
  • Home
  • Media
  • Featured Content
  • Update to U.S. Prescribing Information for Aranesp® and EPOGEN®

  • Overview
  • Fact Sheets
  • Featured Content
  • Press Releases
  • Media Contacts
  • In the News
  • Virtual Press Kits
Update to U.S. Prescribing Information for Aranesp® and EPOGEN®

Amgen is committed to the highest standards of patient safety.

  • Amgen Announces Update to U.S. Prescribing Information for Aranesp® (darbepoetin alfa) and EPOGEN® (Epoetin alfa)
  • Amgen’s Statement on Safety of Aranesp® (darbepoetin alfa) and EPOGEN® (Epoetin alfa)
  • UPDATED: Letter to Healthcare Professionals
  • UPDATED: Prescribing information for Aranesp® (darbepoetin alfa)
  • UPDATED: Prescribing information for EPOGEN® (Epoetin alfa)

 


footer